articleTop 1% cited
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2012 · Vol. 13(10) · pp. 983–992
Karim Fizazi✉(Université Paris-Sud)Howard I. Scher(Memorial Sloan Kettering Cancer Center)Arturo Molina(Janssen (United States))Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center)Kim N.(BC Cancer Agency)Robert J. JonesJohn Staffurth(Velindre NHS Trust)Scott NorthNicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada)Fred Saad(Université de Montréal)Paul N. Mainwaring(Australasia Paediatric Endocrine Group)Stephen Harland(CRUK Lung Cancer Centre of Excellence)Oscar B. GoodmanCora N. Sternberg(Carlo Forlanini Hospital)Jin Hui Li(Janssen (United States))Thian Kheoh(Janssen (United States))Christopher M. Haqq(Janssen (United States))Johann S. de Bono
Prostate Cancer Treatment and ResearchMultiple Myeloma Research and TreatmentsRadiopharmaceutical Chemistry and ApplicationsAbiraterone acetateMedicinePlaceboPrednisoneProstate cancerClinical endpointInterim analysisInternal medicineEnzalutamideDocetaxel
MeSH terms
Abiraterone AcetateAdultAgedAged, 80 and overAndrostadienesCastrationDouble-Blind MethodHumansMaleMiddle AgedNeoplasm MetastasisOrchiectomyProstatic Neoplasms
Citations
1,374
FWCI
95.71
field-weighted impact
References
40
Percentile
100%
vs. same field & year
Citations per year
Cited by
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Oncogene · 2013 · 861 citations
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
European Urology · 2013 · 1,348 citations
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
The Lancet Oncology · 2014 · 1,480 citations
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
European Urology · 2020 · 1,110 citations
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
European Urology · 2016 · 1,439 citations
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Frontiers in Oncology · 2019 · 305 citations
References
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Journal of Clinical Oncology · 2008 · 2,225 citations
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
JNCI Journal of the National Cancer Institute · 2002 · 1,654 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.